Cancer, malaria, and leishmaniasis remain the deadly diseases around the world although several strategies of treatment have been developed. However, most of the drugs used to treat the aforementioned diseases suffer from several pharmacological limitations such as poor pharmacokinetics, toxicity, drug resistance, poor bioavailability and water solubility. Artemisinin and its derivatives are antimalarial drugs. However, they also exhibit anticancer and antileishmanial activity. They have been evaluated as potential anticancer and antileishmanial drugs but their use is also limited by their poor water solubility and poor bioavailability. To overcome the aforementioned limitations associated with artemisinin and its derivatives used for the treatment of these diseases, they have been incorporated into nanoparticles. Several researchers incorporated this class of drugs into nanoparticles resulting in enhanced therapeutic outcomes. Their potential efficacy for the treatment of parasitic infections such as malaria and leishmaniasis and chronic diseases such as cancer has been reported. This review article will be focused on the nanoparticles formulations of artemisinin and derivatives for the treatment of cancer, malaria, and leishmaniasis and the biological outcomes (in vitro and in vivo).

中文翻译：

---

青蒿素及其衍生物的纳米颗粒制剂作为治疗癌症、利什曼病和疟疾的潜在疗法。

尽管已经制定了多种治疗策略，但癌症、疟疾和利什曼病仍然是世界各地的致命疾病。然而，大多数用于治疗上述疾病的药物都存在药代动力学差、毒性、耐药性、生物利用度和水溶性差等药理学局限性。青蒿素及其衍生物是抗疟药。然而，它们还表现出抗癌和抗利什曼活性。它们已被评估为潜在的抗癌和抗利什曼病药物，但它们的使用也因其水溶性差和生物利用度差而受到限制。为了克服与用于治疗这些疾病的青蒿素及其衍生物相关的上述局限性，它们已被纳入纳米颗粒中。一些研究人员将此类药物纳入纳米颗粒中，从而增强了治疗效果。据报道，它们在治疗疟疾和利什曼病等寄生虫感染以及癌症等慢性疾病方面具有潜在功效。这篇综述文章将重点关注用于治疗癌症、疟疾和利什曼病的青蒿素及其衍生物的纳米颗粒制剂及其生物学结果（体外和体内）。